D-ALLULOSE FOR IMPROVING AUTISM SPECTRUM DISORDER AND MENTAL DISEASE

An object of the present invention is to provide a novel pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect. The present invention also provides a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin in the brain. The above objects are achieved by a pharmaceutical agent for improving autism spectrum disorder, a pharmaceutical agent for improving a mental disease, or a supplement exerting an effect of improving social behaviors or developing sociality or an anti-anxiety and anti-stress effect or a functional food exerting such an effect, or a pharmaceutical agent for promoting the secretion of oxytocin and/or vasopressin, which comprises D-allulose as an active ingredient..

Medienart:

Patent

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Europäisches Patentamt - (2024) vom: 13. März Zur Gesamtaufnahme - year:2024

Sprache:

Englisch

Beteiligte Personen:

YADA TOSHIHIKO [VerfasserIn]
IWASAKI YUSAKU [VerfasserIn]
SUYAMA SHIGETOMO [VerfasserIn]

Links:

Volltext [kostenfrei]

Themen:

Sonstige Themen:
615
A23L: Foods, foodstuffs, or non-alcoholic beverages, not (...)
A61K: Preparations for medical, dental, or toilet purpose (...)
A61P: Specific therapeutic activity of chemical compounds (...)
che
tec

Anmerkungen:

Source: www.epo.org (no modifications made), First posted: 2024-03-13, Last update posted on www.tib.eu: 2024-03-26, Last updated: 2024-03-29

Patentnummer:

EP3744332

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

EPA00091830X